Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland
February 5, 2025 | Branding, Creative and Design, Digital Communications, Equitable access, Health policy and government affairs, Market Access, Medical Communications, Patient support and adherence, Sales, cell and gene therapy, clinical research, medical education, pharmacy, regulatory affairs
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global markets.
The new facilities, located in Raleigh, USA, Lelystad, Netherlands, and Dublin, Ireland, reflect Uniphar’s commitment to enhancing its logistics and distribution capabilities within global pharmaceutical and healthcare sectors.
With 57 years’ industry experience, Uniphar’s new facilities position the company to support pharmaceutical and biotech companies more effectively, offering comprehensive solutions that cover the entire product lifecycle. The new locations aim to ensure the timely delivery of critical therapies to patients worldwide, whilst supporting pharmaceutical companies to navigate complex market access challenges, from clinical trials to global product launches.
The Raleigh, North Carolina facility, covering 65,000 sq. ft., is a GMP & GDP pharma-grade storage facility designed to handle ambient, cold-chain, and freezer storage requirements. It includes dedicated clean rooms for clinical trials, a DEA-approved controlled drugs vault for Schedule II to V drugs, and a fully integrated Warehouse Management System for seamless operations. The facility is equipped with redundant power supply, temperature & humidity monitoring systems, and advanced inventory management, ensuring compliance with the FDA, ISO, and DSCSA regulations.
In Lelystad, the G-Park Lelystad facility represents Uniphar’s flagship European facility, positioned within the Lelystad Airport Business Park, one of the most strategically located logistics hubs in Europe. This Grade A facility spans 9,000 m² and includes narrow-aisle high-bay racking, controlled ambient storage, and segregated quarantine zones. With its BREEAM Excellent rating, the facility is built with sustainable features, including solar energy and a triple redundant power supply, designed to minimise environmental impact. Located just 200 metres from the A6 motorway, it offers exceptional connectivity to key European markets, including the Netherlands, Germany, Austria, the UK, and Ireland.
The facility in Dublin, Ireland, is the newest addition to its global network. At 35,000 sq. m., this new facility is designed to support the increasing demand for cold-chain logistics with 1,100 pallets of cold storage capacity and built to LEED Gold standards, it ensures the highest environmental and sustainability criteria. With a modern layout to optimise material flows and segregated zones for quarantine, recall, and returns management, the Dublin facility is a key enabler of Uniphar’s ability to scale its operations and its commitment to enabling healthcare.
In addition to these three new facilities, Uniphar’s global network now encompasses 22 strategically located facilities across Europe, North America, and other key regions. This extensive footprint enables Uniphar to deliver unparalleled logistical solutions for specialty medicines, biologics, and advanced therapies, ensuring timely and efficient access to innovative treatments in over 180 countries worldwide.
With a global footprint delivering specialist services to more than 200 international clients across 180 countries, Uniphar’s new facilities are strategically positioned to meet the growing demand for specialty and complex medicines, including biologics, cell and gene therapies, and cold-chain products.
“These expansions are a direct response to the increasing complexity of launching innovative therapies in diverse and often challenging global markets. Uniphar’s ability to provide end-to-end solutions, from clinical trial support to product launch and distribution, is what sets us apart as a leader in the global pharmaceutical logistics and supply chain space. This milestone reflects our commitment to driving excellence in pharmaceutical logistics and underscores our long-term strategy to support the development and delivery of innovative therapies globally.” said Dermot Ryan, Chief Operating Officer at Uniphar.
For more information on Uniphar, visit www.Uniphar.com/Pharma
ENDS
For media enquiries, please contact:
Heather Hopkin at TALA at heather.hopkin@teamtala.com
Beth O’Shea at TALA at beth.oshea@teamtala.com
About Uniphar
Uniphar Group is a trusted global partner to pharma, medtech and biotech companies, working to improve patient access to medicines around the world. Uniphar’s team of experts harness the capabilities, infrastructure and expertise of a diversified pharmaceutical service provider with more than 57 years’ building success stories with 200+ multinational clients.
Our understanding of the shifting market dynamics allows us to deliver tailored specialist services and solutions for our clients’ changing needs. Uniphar Pharma comprises Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial – together our combined capabilities make us your trusted partner to unlock access for your patients to innovative therapies and optimize value for brands globally. Working from clinical development to commercialization, our end-to-end services remove barriers to launch, increase access and optimize brands.
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
- New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. - Mike Ebhardt is appointed President of Uniphar Pharma...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
Uniphar Secures 10th Cell and Gene Therapy Project
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s...
Uniphar Expands Global Footprint with Three New Facilities in the USA, Netherlands and Ireland
[Dublin, 05 February 2025] Global partner to pharmaceutical and medtech manufacturers, Uniphar, is expanding its international presence with the launch of three new, state-of-the-art facilities, strategically positioned across key global...
- 1
- 2